How an EMA Referral Changes the SmPC, Package Leaflet and Risk Management Plan

Introduction

One of the most visible consequences of an EU referral is a change to the regulatory framework under which a medicine is authorised and used.

For a safety referral, that change may be reflected in the Summary of Product Characteristics (SmPC), the labelling, the Package Leaflet (PL), the Risk Management Plan (RMP), additional pharmacovigilance activities, additional risk-minimisation measures, or a combination of these.

These documents should not be treated as interchangeable versions of the same information.

The SmPC is the professional product-information document defining the authorised information for healthcare professionals. The Package Leaflet translates relevant information for patients and users. The RMP is a pharmacovigilance risk-management document describing identified and potential risks, missing information and the measures used to characterise and manage those risks.

A referral can therefore change several different regulatory layers at once.

The practical sequence is better understood as:

Safety concern
      ↓
Scientific assessment
      ↓
PRAC recommendation
      ↓
CHMP / CMDh consideration
      ↓
Legally operative regulatory outcome
      ↓
Product-information changes
      ↓
RMP / PV / risk-minimisation changes
      ↓
Implementation and verification
      ↓
Ongoing monitoring

The exact outcome depends on the legal basis, products concerned and conclusions of the procedure. A referral does not automatically mean that every section of the SmPC, every part of the Package Leaflet or the RMP will change.

The key regulatory skill is therefore to understand how the scientific conclusion is translated into the appropriate regulatory instruments.

1. A Referral Does Not Automatically Mean a Label Change

A referral can conclude in different ways.

Depending on the procedure and the evidence, the regulatory outcome can include maintenance of the marketing authorisation, variation of the authorisation, restrictions or other measures provided for by the applicable legal framework.

For example, current EMA information on Article 20 pharmacovigilance procedures states that CHMP considers the PRAC recommendation and assessment report and adopts an opinion on maintenance, variation, suspension or revocation of the marketing authorisations concerned. citeturn0search4

For an Article 31 pharmacovigilance referral, the products and procedural pathway depend on the scope of the safety issue and whether centrally or nationally authorised medicines are involved. citeturn0search2

Therefore the first question after a referral is not:

“Which SmPC section needs to be changed?”

It is:

“What regulatory conclusion has actually been adopted, and what authorised conditions or risk-management requirements follow from it?”

Only then can the document-level consequences be determined.

2. The Regulatory Documents Have Different Functions

A useful starting point is to separate the main instruments.

The same scientific conclusion can therefore appear in several instruments, but it does not appear in exactly the same form.

For example, a newly characterised risk may require a warning in the SmPC, corresponding patient information in the Package Leaflet, an update to the RMP and an additional risk-minimisation measure. Alternatively, the scientific conclusion may require only one of these actions.

The regulatory outcome determines the combination.

3. From Scientific Conclusion to Authorised Product Information

The transition from scientific assessment to product information is not simply a matter of copying the wording of a PRAC assessment report into the SmPC.

The scientific assessment explains why the committee reached its conclusion.

The product information expresses what is authorised and how the medicine should be used in light of that conclusion.

That distinction is fundamental.

An assessment report can contain extensive discussion of:

• individual cases;
• epidemiological findings;
• alternative explanations;
• biological plausibility;
• uncertainty;
• subgroup analyses;
• benefit-risk considerations; and
• regulatory options.

The final SmPC cannot reproduce that entire scientific discussion. It must express the relevant authorised information in the appropriate sections and terminology.

Consequently, the drafting exercise requires regulatory and medical judgement within the boundaries established by the final regulatory outcome.

4. Which SmPC Sections Can Be Affected?

The appropriate section depends on the regulatory conclusion.

Safety-related referral outcomes can affect, among others:

• Section 4.3 — Contraindications;
• Section 4.4 — Special warnings and precautions for use;
• Section 4.5 — Interaction with other medicinal products and other forms of interaction;
• Section 4.6 — Fertility, pregnancy and lactation, where relevant;
• Section 4.8 — Undesirable effects;
• Section 4.9 — Overdose, where relevant; and
• other sections when the safety conclusion affects dosing, monitoring, use or other authorised information.

The section should follow the nature of the regulatory conclusion, not the origin of the safety signal.

For example, an adverse reaction identified through pharmacovigilance may result in a warning in Section 4.4, a new adverse reaction in Section 4.8, or a contraindication in Section 4.3, depending on the clinical and regulatory assessment.

It is therefore incorrect to assume that every safety referral produces a Section 4.8 change.

5. Section 4.4 and Section 4.8 Do Different Jobs

This distinction is particularly important in pharmacovigilance practice.

Section 4.4 — Special warnings and precautions for use

Section 4.4 communicates clinically important information about risks and the precautions required for safe use.

The emphasis is therefore on what the prescriber or healthcare professional needs to know in order to use the medicine safely.

Depending on the risk, this can include information about:

• patient selection;
• risk factors;
• monitoring;
• early recognition of an adverse event;
• management of a risk;
• circumstances requiring treatment interruption or discontinuation; or
• other precautions necessary for safe use.

Section 4.8 — Undesirable effects

Section 4.8 provides information on adverse reactions and their frequency categories or other applicable presentation requirements.

The two sections can therefore work together.

A clinically important adverse reaction may be listed in Section 4.8 while the circumstances requiring particular caution are described in Section 4.4.

The presence of an adverse reaction in Section 4.8 does not by itself determine whether a warning belongs in Section 4.4.

The regulatory drafting should reflect the clinical purpose of the information.

6. When a Referral Leads to a Contraindication

A contraindication is a stronger regulatory intervention than simply listing an adverse reaction.

If the scientific and benefit-risk assessment establishes that the medicine should not be used in a specified circumstance, the regulatory outcome may require a contraindication in Section 4.3.

The wording should correspond precisely to the population or circumstance covered by the final decision.

This is an important example of why product-information drafting must follow the regulatory conclusion rather than precede it.

The MAH should not broaden a contraindication simply because a broader statement appears commercially or medically cautious. Conversely, it should not narrow a legally adopted contraindication to reduce its operational impact.

The final authorised wording is controlled by the applicable regulatory outcome.

7. How the Package Leaflet Follows the SmPC

The Package Leaflet is intended for patients and users rather than healthcare professionals.

When a referral changes clinically relevant safety information, the corresponding patient-facing information may therefore need to change as well.

The relationship is not a word-for-word translation.

The same regulatory conclusion must be expressed in language and structure appropriate for patients.

For example, a professional warning concerning a risk factor and monitoring requirement may need to become patient-facing information explaining:

• who may be at risk;
• what symptoms require attention;
• what the patient should do; and
• when medical advice should be sought.

The patient information must remain consistent with the authorised SmPC while serving its different communication purpose.

This is why a referral can create substantial implementation work even when the scientific conclusion itself is concise.

8. Product Information Is a Controlled Regulatory Output

A product-information change should be treated as a controlled regulatory implementation activity.

The company needs to establish:

1. the exact legally adopted wording;
2. which product-information documents are affected;
3. which language versions are required;
4. the applicable implementation mechanism;
5. the responsible regulatory functions;
6. the required packaging or artwork consequences, where applicable; and
7. evidence that implementation was completed.

The precise mechanism differs according to the authorisation route and procedure.

For referral procedures, EMA maintains specific guidance on product-information translations and linguistic review. Current EMA guidance explains that linguistic review follows adoption of CHMP opinions or CMDh positions and forms part of the Commission decision-making process. citeturn0search5

Current Article 31 guidance also specifies the handling of translations and distinguishes implementation for centrally authorised and nationally authorised products. citeturn0search0

The MAH therefore needs to distinguish adoption of the regulatory wording from completion of all implementation activities.

9. The RMP Is Not a Second SmPC

The RMP has a different purpose.

The RMP describes how important risks and missing information are characterised and how they are managed and monitored. It is part of the pharmacovigilance and risk-management framework rather than simply another product-information document.

A referral can therefore result in an RMP update even where the corresponding product-information change is relatively limited.

For example, a referral may conclude that:

• a risk requires additional monitoring;
• an important potential risk requires further characterisation;
• a missing-information category needs to be addressed;
• a post-authorisation study is required or modified; or
• an additional risk-minimisation measure is necessary.

The RMP should then reflect the regulatory conclusion and the resulting risk-management strategy in accordance with the applicable requirements.

The RMP is consequently a management and monitoring framework for risk, whereas the SmPC is part of the authorised product information.

10. How a Referral Can Change the RMP

The exact RMP consequence depends on what the referral establishes.

Potential changes can concern:

• important identified risks;
• important potential risks;
• missing information;
• additional pharmacovigilance activities;
• routine pharmacovigilance;
• additional risk-minimisation measures;
• effectiveness evaluation of risk-minimisation measures; or
• the overall risk-management strategy.

The company should not automatically add every discussed safety concern to the RMP.

The RMP should reflect the regulatory conclusion and the applicable RMP methodology, including the distinction between identified risks, potential risks and missing information.

This is particularly important because a scientific discussion can contain uncertainties that do not necessarily become formal RMP elements.

The RMP is therefore not a transcript of the referral assessment.

11. Product Information and RMP Must Remain Consistent

Although the SmPC and RMP have different functions, they cannot be managed independently.

A referral that changes the characterisation of a risk may require coordinated changes across:

Regulatory conclusion
        ↓
SmPC / PL / labelling
        ↓
RMP
        ↓
Risk-minimisation measures
        ↓
PV activities
        ↓
Monitoring of the risk

The wording does not have to be identical across these instruments.

It does, however, need to represent the same underlying regulatory conclusion.

For example, if a risk is newly recognised as important and requires additional risk minimisation, the company should be able to explain how the SmPC warning, patient information, RMP and additional measure fit together.

Inconsistency between these elements can create both regulatory and inspection problems.

12. The Regulatory Outcome Determines the Implementation Path

The same scientific issue can have different implementation consequences depending on the authorisation route.

For centrally authorised medicines, the European Commission decision creates the legally operative Union outcome, with the subsequent product-information implementation occurring through the centralised framework.

For nationally authorised medicines, including medicines authorised through mutual recognition or decentralised procedures, implementation involves the applicable Member State framework following the Union-level outcome.

Current EMA Article 31 guidance expressly distinguishes the two pathways and provides for translation and subsequent Commission decision-making, with the decision addressed according to whether centrally or nationally authorised products are concerned. citeturn0search0

This is one reason why an apparently simple safety conclusion can produce substantially different operational workloads for different MAHs.

13. The QPPV's Role in Product-Information and RMP Changes

The QPPV should not be regarded as the sole owner of product-information drafting or regulatory submission activities.

The QPPV's responsibility is to maintain appropriate oversight of the pharmacovigilance system and to ensure that relevant safety information is appropriately identified, assessed, communicated and reflected in the system's regulatory interfaces.

In practice, the QPPV should be able to understand:

• what risk the referral has established;
• how the risk has been characterised;
• what product-information changes are proposed or adopted;
• whether the RMP needs modification;
• whether additional pharmacovigilance activities are required;
• whether additional risk-minimisation measures are imposed; and
• how implementation will affect ongoing safety monitoring.

The QPPV should also be alert to discrepancies between the final regulatory conclusion and the assumptions embedded in existing PV procedures.

A referral can therefore trigger a broader pharmacovigilance-system review even when the immediate regulatory action appears to be limited to product information.

14. From Regulatory Wording to Controlled Implementation

Once the final regulatory outcome is known, the MAH must translate it into controlled operational actions.

The implementation process should begin with the final legally operative wording and its annexes, not with an earlier draft recommendation.

A useful implementation chain is:

Final regulatory outcome
        ↓
Identify exact requirements
        ↓
Map requirements to documents and systems
        ↓
Assign implementation owners
        ↓
Update controlled documents
        ↓
Complete required regulatory procedures
        ↓
Implement product-information changes
        ↓
Implement RMP / PV / risk-minimisation changes
        ↓
Verify completion
        ↓
Maintain evidence of implementation

The implementation plan should distinguish actions that are legally required from actions that the company chooses to undertake as part of good governance.

For example, an internal training session may be an appropriate company control following a major label change. That does not mean the training session itself is necessarily an EU legal requirement.

This distinction matters when implementation plans are later reviewed during inspections.

15. The Difference Between Authorised Wording and Supporting Explanation

A referral assessment report may contain extensive reasoning supporting a regulatory conclusion.

The final product information will normally be much shorter.

This does not mean that the scientific reasoning has been lost. The reasoning supports the regulatory outcome, while the product information expresses the resulting authorised conditions of use.

The MAH should therefore avoid treating explanatory material from an assessment report as though it were automatically approved product-information language.

The same principle applies in reverse.

A concise warning in the SmPC may represent a substantial body of evidence and regulatory reasoning that is not reproduced in the label itself.

For regulatory professionals, the two documents should be read together when reconstructing why a particular product-information change was made.

16. Additional Risk-Minimisation Measures

A referral may establish that routine product information alone is insufficient to manage a particular risk.

In such circumstances, the regulatory outcome may require additional risk-minimisation measures.

These measures can include tools or interventions designed to support safe use beyond the information contained in routine product information.

The important point is that the additional measure must be linked to the specific risk and its management objective.

The MAH should therefore be able to answer:

• What risk is the measure intended to address?
• What behaviour or clinical action is it intended to influence?
• Which population is affected?
• How will the measure be implemented?
• How will its effectiveness be evaluated where required?
• How does it relate to the SmPC and Package Leaflet?

The RMP provides the framework in which these measures are documented and managed.

A referral-driven additional risk-minimisation measure is therefore not an isolated communication project. It becomes part of the controlled risk-management system.

17. Additional Pharmacovigilance Activities

The regulatory conclusion may also determine that the available evidence is insufficient to fully characterise a risk.

The response may then involve additional pharmacovigilance activities.

Depending on the individual case, the RMP may include activities designed to further characterise:

• the frequency of an event;
• the severity or clinical course;
• risk factors;
• affected populations;
• exposure circumstances; or
• other important uncertainties.

The distinction from additional risk minimisation is important.

Risk minimisation attempts to reduce the occurrence or consequences of a risk.

Additional pharmacovigilance seeks to generate or obtain information needed to better understand a risk or missing information.

A referral can require one, the other, or both.

18. Effectiveness of Risk-Minimisation Measures

Where a referral introduces or strengthens risk-minimisation measures, the company may also need to assess whether those measures are achieving their intended purpose.

The relevant assessment should be linked to the regulatory objective.

For example, if a measure is intended to improve prescriber recognition of a specific risk, the evaluation should address whether the relevant knowledge or behaviour has changed rather than merely documenting that the educational material was distributed.

The exact requirements depend on the regulatory outcome and applicable risk-management guidance.

The broader principle is that implementation and effectiveness are different questions:

A measure can be implemented correctly without necessarily being effective.

This distinction is particularly important for the QPPV because ineffective risk minimisation can itself become a new regulatory concern.

19. Translations and Linguistic Implementation

EU product-information changes do not end with agreement on the English text.

Where the applicable procedure requires translations, the approved wording must be implemented through the relevant linguistic and regulatory processes.

The MAH therefore needs to control:

• the source text;
• translated versions;
• linguistic review;
• agreed terminology;
• final approved versions; and
• the transition from regulatory text to market implementation.

The exact process differs by procedure and authorisation route.

EMA's referral guidance provides procedure-specific information on translation and linguistic review following committee opinions or positions. The company should follow the current instructions applicable to the individual procedure rather than applying a generic translation workflow.

This is an important operational point: a scientific conclusion may be common across the Union while the implementation record is distributed across multiple languages and, for nationally authorised products, multiple national authorisations.

20. Packaging and Artwork Consequences

A change to product information can have consequences beyond the SmPC and Package Leaflet files themselves.

Depending on the nature of the change, the MAH may need to assess:

• labelling text;
• packaging components;
• artwork;
• printed materials;
• electronic product-information systems; and
• controlled manufacturing or distribution processes.

The existence of such work does not mean that every referral requires an immediate physical packaging change.

The operational consequence depends on what the final regulatory decision changes and on the applicable implementation requirements.

The MAH should therefore perform an explicit implementation impact assessment rather than assuming that a document revision automatically means a manufacturing change.

21. The Regulatory Change-Control Perspective

A referral outcome should normally enter the company's established regulatory change-control system.

The change-control record should make clear:

• the source of the change;
• the final regulatory requirement;
• the affected products and markets;
• the affected documents and systems;
• implementation owners;
• dependencies;
• required approvals; and
• evidence of completion.

This provides a bridge between the external regulatory decision and the company's internal quality system.

It also prevents an important failure mode: the regulatory team may consider a referral closed while operational functions have not completed all downstream actions.

22. What Happens When the Referral Changes the Safety Profile?

A referral can change more than the wording of the label.

If the regulatory conclusion materially changes the understanding of a risk, the MAH should assess whether the broader pharmacovigilance system remains aligned with the new safety profile.

Potential areas for review include:

• signal-detection configurations;
• medical-review criteria;
• case follow-up strategies;
• coding conventions where relevant;
• case-series monitoring;
• aggregate-reporting assessments;
• RMP activities;
• safety specifications;
• routine and additional risk-minimisation measures; and
• ongoing signal monitoring.

The exact actions depend on the regulatory conclusion.

The key principle is that the label change is an output of the safety assessment, not necessarily the end of the safety-system work.

23. Regulatory Information Must Remain Internally Consistent

After a major referral, the company may have many controlled sources describing the product's safety profile.

These can include:

• SmPC;
• Package Leaflet;
• RMP;
• core safety information;
• safety database configuration;
• signal-management documentation;
• aggregate reports;
• pharmacovigilance procedures;
• medical information content; and
• training or educational materials.

Not every document will use identical wording.

They should nevertheless remain consistent with the final regulatory conclusion and with one another where the same underlying safety fact is being described.

An inconsistency can create operational confusion and may also become an inspection finding if it demonstrates inadequate control of safety information.

A referral therefore provides a useful opportunity for a cross-system consistency review.

24. CAP Versus NAP: Why Implementation Can Look Different

The authorisation route matters throughout the implementation phase.

For a centrally authorised product, the Union-level decision and associated product-information process provide the framework for implementation across the centrally authorised product.

For nationally authorised products, the regulatory outcome must be reflected through the applicable national or coordinated procedures.

This means that the MAH should maintain an authorisation-level inventory.

For each affected authorisation, the company should know:

• the legal status;
• the applicable implementation procedure;
• the current product-information version;
• the required revised version;
• the status of national implementation where applicable; and
• the evidence demonstrating completion.

A global statement such as “the label has been updated” may therefore be inadequate for a portfolio containing multiple authorisations.

25. What the QPPV Should Verify

The QPPV does not need to personally perform every regulatory implementation activity.

The QPPV should, however, have sufficient oversight to establish that the pharmacovigilance consequences of the regulatory decision have been addressed.

A practical QPPV review can ask:

Safety conclusion

What exactly has the regulator concluded about the risk?

Product information

Does the final authorised information accurately reflect that conclusion?

Risk management

Does the RMP reflect the new risk characterisation and required measures?

Pharmacovigilance

Have relevant PV processes, monitoring and reporting activities been assessed?

Risk minimisation

Are additional measures implemented as required, and is their effectiveness being evaluated where applicable?

Governance

Can the company demonstrate who implemented each action and how completion was verified?

Future evidence

What residual uncertainty remains, and how will it be monitored?

This review connects the regulatory decision back to the QPPV's continuing oversight of the pharmacovigilance system.

26. Common Implementation Errors

Treating the PRAC recommendation as the final wording

The company should implement the legally operative outcome, not an earlier recommendation that may subsequently have changed.

Updating the SmPC but not the RMP

Where the regulatory conclusion affects risk management, the RMP should be assessed separately rather than assumed to be unaffected.

Treating the RMP as a duplicate of the label

The two documents serve different regulatory purposes.

Assuming a Section 4.8 change is sufficient

A safety issue may also require warnings, contraindications, monitoring information or risk-minimisation measures.

Treating translation as a purely linguistic exercise

Regulatory terminology and consistency with the adopted source wording matter.

Closing the change-control record before downstream implementation is complete

The regulatory document may be approved while operational implementation remains outstanding.

Failing to review the wider PV system

A major change in risk characterisation can affect ongoing safety activities beyond product information.

27. Inspection Perspective

A referral-related product-information change can provide inspectors with a useful test of the company's regulatory and pharmacovigilance control system.

The company should be able to demonstrate a traceable chain:

Regulatory decision
      ↓
Internal impact assessment
      ↓
Change-control / implementation plan
      ↓
Document updates
      ↓
PV / RMP / risk-minimisation updates
      ↓
Review and approval
      ↓
Implementation
      ↓
Verification

An inspector may reasonably want to understand not only whether the final SmPC is correct, but whether the company recognised and implemented all related pharmacovigilance consequences.

The precise inspection expectations depend on the applicable legal requirements and the circumstances of the inspection.

The practical lesson is simple: regulatory implementation should leave an auditable evidence trail.

28. The Regulatory Outcome Is the Starting Point for the Next Lifecycle Phase

The final product-information change should not be regarded as the endpoint of the process.

It becomes the new regulatory baseline against which future safety information is interpreted.

The lifecycle therefore continues:

Referral outcome
      ↓
New authorised safety information
      ↓
Updated RMP / PV system
      ↓
Routine monitoring
      ↓
New evidence
      ↓
New assessment if necessary
      ↓
Further variation / referral / other regulatory action

A referral can therefore alter the starting point for future pharmacovigilance.

A risk newly recognised during the referral may become an established safety consideration in subsequent signal detection, aggregate reporting and risk-management activities.

This is one of the most important practical consequences of a referral for the QPPV.

Key Takeaways

1. A referral does not automatically produce a product-information change; the final regulatory outcome determines what must change.
2. The SmPC, Package Leaflet, labelling and RMP have different regulatory functions.
3. The assessment report explains the scientific reasoning, while the authorised product information expresses the resulting conditions of use.
4. Safety conclusions can affect different SmPC sections depending on their clinical and regulatory implications.
5. Section 4.4 and Section 4.8 serve different purposes and should not be treated as interchangeable.
6. A Package Leaflet change must communicate the authorised safety information appropriately to patients and users rather than simply reproduce professional wording.
7. The RMP is a risk-management framework, not a second version of the SmPC.
8. A referral may require changes to additional pharmacovigilance activities, additional risk-minimisation measures, or both.
9. Product information and RMP changes should remain consistent with the same underlying regulatory conclusion even though their wording and purposes differ.
10. Implementation can involve translations, national procedures, packaging or artwork, regulatory systems and internal change control depending on the outcome.
11. The QPPV should maintain oversight of the pharmacovigilance consequences of the regulatory decision rather than personally owning every implementation task.
12. A referral-related label change can alter the future baseline for signal management and ongoing pharmacovigilance.
13. The implementation process should leave a clear, auditable chain from the legally operative regulatory outcome to completed company actions.

References

1. European Parliament and Council. Regulation (EC) No 726/2004, as amended. Legal framework for Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products.
2. European Parliament and Council. Directive 2001/83/EC, as amended. Community code relating to medicinal products for human use, including product information, pharmacovigilance and referral provisions.
3. European Commission. Guideline on the packaging information of medicinal products for human use authorised by the Union. Current EU guidance on the presentation and content of packaging information.
4. European Commission. Guideline on the readability of the label and package leaflet of medicinal products for human use. Current EU guidance concerning patient-facing product information.
5. European Medicines Agency. Questions and answers: Article 20 pharmacovigilance procedures. Current procedure-specific information concerning PRAC recommendations, CHMP opinions and product-information consequences.
6. European Medicines Agency. Questions and answers: Article 31 pharmacovigilance referrals. Current procedure-specific information concerning referrals involving centrally and nationally authorised medicines and subsequent implementation.
7. European Medicines Agency. Questions and answers: Article 31 non-pharmacovigilance referrals. Current information concerning product-information implementation following applicable referral outcomes.
8. European Medicines Agency. Referral procedures for human medicines. Current overview of EU referral mechanisms and procedural implementation.
9. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module V — Risk Management Systems. Current guidance concerning risk-management plans, risk characterisation and risk-minimisation measures.
10. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module I — Pharmacovigilance systems and their quality systems. Current guidance relevant to pharmacovigilance governance and quality systems.
11. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module IX — Signal Management. Current guidance concerning signal management and continuing safety monitoring.
12. European Medicines Agency. QRD product-information templates and related guidance. Current templates and guidance should be consulted when implementing changes to EU product information.

Regulatory Note

This article is an educational explanation of how an EU referral can affect product information, risk-management documentation and pharmacovigilance activities. It is not legal advice and does not replace the applicable EU legislation, current EMA guidance, European Commission guidance, GVP, national requirements or the formal documents governing an individual referral.

The exact product-information wording, implementation mechanism, timetable, translation requirements, national procedures and RMP consequences depend on the legal basis, authorisation route, products concerned and final regulatory outcome.

The article deliberately distinguishes the scientific assessment from the legally operative regulatory outcome and from subsequent company implementation. A PRAC recommendation should not be treated as though it were automatically the final authorised wording.

The practical implementation models described in this article are not universal statutory checklists. Internal MAH governance, change-control processes and assignment of responsibilities may differ between organisations. What is essential is compliance with the applicable regulatory requirements and effective control of the resulting pharmacovigilance and regulatory changes.

For an active referral, the current legislation, referral notification, adopted committee documents, final legally operative decision, current product-information templates and procedure-specific implementation instructions should take precedence over this general explanation.

29. Reading a Referral Outcome as an Implementation Map

A useful way to work with a completed referral is to read the final regulatory documents as an implementation map rather than as a single conclusion.

The MAH should identify, separately:

1. the scientific conclusion;
2. the legally operative decision or position;
3. the affected products and authorisations;
4. the exact product-information amendments;
5. any conditions or restrictions;
6. any risk-management consequences;
7. any additional pharmacovigilance activities;
8. any additional risk-minimisation measures; and
9. the evidence required to demonstrate implementation.

This approach prevents a common error: treating the entire referral as though it resulted in one undifferentiated “label change”.

Current EMA referral guidance illustrates this separation. For Article 31 procedures, the CHMP opinion can contain the scientific grounds, the wording to be included in product information, applicable conditions or restrictions, the assessment report and, where applicable, a DHPC and communication plan. The subsequent Commission decision is the binding regulatory decision. citeturn0search0

The documents therefore answer different questions and should be retained and interpreted accordingly.

30. The Product-Information Change Is a Controlled Version Change

Once the applicable regulatory outcome has been adopted, the revised product information becomes a controlled version of the authorised information.

The MAH should be able to establish:

• which version was previously authorised;
• what regulatory event caused the change;
• what wording changed;
• which products and presentations are affected;
• when the revised version became applicable; and
• what implementation evidence exists.

This is more than document control in the narrow administrative sense.

The product information is an external expression of the authorised conditions of use. A failure to control its transition can therefore create a discrepancy between the regulatory state of the product and the information actually used in practice.

For referral procedures, EMA provides specific procedural and linguistic guidance. Current guidance states that linguistic review of referral product information follows adoption of the relevant CHMP opinion or CMDh position and forms part of the applicable Commission decision-making process. citeturn0search4

31. Why the RMP May Continue to Change After the Label Change

The RMP is dynamic.

Current GVP Module V describes the RMP as a document that should be updated throughout the product lifecycle. Its safety concerns can be added, reclassified or removed as the safety profile becomes better characterised, while additional pharmacovigilance and risk-minimisation activities may also change over time. citeturn0search26

This means that the RMP consequence of a referral should not be viewed as a one-time administrative update.

A referral may establish a new risk, change the importance of an existing risk, alter the residual uncertainty, or change the measures required to manage the risk. The resulting RMP may therefore become the basis for subsequent monitoring and future regulatory reassessment.

The label and RMP consequently operate on different but connected timescales.

32. The Difference Between Immediate Implementation and Lifecycle Follow-Up

It is useful to distinguish two phases.

Immediate implementation

This concerns actions required to put the regulatory outcome into effect, such as applicable product-information changes, translations, regulatory submissions, risk-minimisation materials and required system updates.

Lifecycle follow-up

This concerns actions that continue after implementation, such as additional pharmacovigilance activities, effectiveness evaluation, signal monitoring and assessment of new evidence.

The distinction matters because a company can complete immediate implementation while still having substantial regulatory obligations arising from the referral.

The referral is therefore not necessarily “closed” from a pharmacovigilance perspective merely because the revised SmPC has been approved.

33. What an Experienced QPPV Looks For

An experienced QPPV will generally look beyond whether the final label is technically correct.

The more important question is whether the regulatory conclusion has been incorporated into the pharmacovigilance system as a whole.

The QPPV should be able to reconstruct the chain:

Safety evidence
      ↓
Regulatory assessment
      ↓
Final regulatory conclusion
      ↓
Authorised product information
      ↓
RMP and risk-management measures
      ↓
PV system implementation
      ↓
Ongoing monitoring

The QPPV should also understand where uncertainty remains.

For example, a referral can establish that an association represents an important identified risk while leaving uncertainty about its incidence in a particular population. The regulatory response may therefore combine a warning with further pharmacovigilance.

That is not an inconsistency. It reflects the fact that regulatory action can both manage a known risk and continue to characterise what remains uncertain.

34. A Practical Referral-to-Implementation Checklist

For operational use, the following checklist provides a useful starting point.

The checklist is deliberately not presented as a statutory EU procedure. It is a practical governance framework for ensuring that the actual regulatory requirements have not been lost during implementation.

35. Final Perspective

An EU referral can appear to end when the committee adopts its conclusion or when the European Commission adopts the binding decision. For the MAH and QPPV, however, that is better understood as a transition point.

The scientific conclusion must be translated into the authorised product information. Where required, the risk-management system must then be changed so that the new understanding of the product's risks is reflected in ongoing pharmacovigilance and risk-minimisation activities.

The most important conceptual distinction is between assessment, authorisation and implementation.

The assessment explains the evidence and scientific reasoning.

The regulatory decision establishes the legally operative outcome.

The product information expresses the authorised conditions of use.

The RMP and pharmacovigilance system provide the framework for managing and monitoring risks through the remainder of the product lifecycle.

A strong MAH therefore does not treat the referral outcome as a document-editing exercise. It treats it as a controlled change to the product's regulatory and pharmacovigilance state.

For the QPPV, the central question is not simply:

“Has the SmPC been changed?”

It is:

“Has the regulatory conclusion been accurately and completely incorporated into the pharmacovigilance system, and can the organisation demonstrate that this has been achieved?”

That is the point at which referral management connects directly to lifecycle pharmacovigilance.

References

1. European Parliament and Council. Directive 2001/83/EC, as amended. Union code relating to medicinal products for human use, including provisions governing product information, pharmacovigilance and referral procedures.
2. European Parliament and Council. Regulation (EC) No 726/2004, as amended. Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products and the legal framework establishing EMA.
3. European Medicines Agency. Questions and answers: Article 20 pharmacovigilance procedures. Current EMA procedural guidance concerning Article 20 procedures, committee assessment and resulting regulatory actions.
4. European Medicines Agency. Questions and answers: Article 31 pharmacovigilance referrals. Current EMA procedural guidance concerning pharmacovigilance referrals involving centrally and nationally authorised medicines.
5. European Medicines Agency. Questions and answers: Article 31 non-pharmacovigilance referrals. Current procedural guidance concerning CHMP opinions, product-information wording, translations and Commission decision-making. Updated July 2026. citeturn0search0
6. European Medicines Agency. Referral procedures: Regulatory and procedural guidance. Current guidance concerning referral product information, translations and QRD requirements. citeturn0search4
7. European Medicines Agency. Good Pharmacovigilance Practices, Module V — Risk Management Systems. Current guidance on risk-management systems, RMP structure, safety concerns, pharmacovigilance activities and risk-minimisation measures. citeturn0search8turn0search26
8. European Medicines Agency. Good Pharmacovigilance Practices, Module I — Pharmacovigilance systems and their quality systems. Guidance relevant to pharmacovigilance governance, quality systems and oversight.
9. European Medicines Agency. QRD product-information templates and referral guidance. Current templates and procedural material should be consulted when implementing amendments to EU product information.
10. European Commission. Notice to Applicants, Volume 2A, Chapter 6 — Decision Making Procedure for the Adoption of Commission Decisions. Relevant procedural framework for Commission decisions following applicable procedures.

Regulatory Note

This article is an educational explanation of how an EU referral can translate into changes to the SmPC, labelling, Package Leaflet, Risk Management Plan and pharmacovigilance system. It is not legal advice and does not replace the applicable EU legislation, current EMA and European Commission guidance, GVP, national requirements or the formal documents governing an individual procedure.

The exact regulatory consequences depend on the legal basis of the referral, the authorisation route, the products concerned and the final legally operative outcome. Not every referral produces the same combination of product-information, RMP, pharmacovigilance or risk-minimisation changes.

The article deliberately distinguishes scientific assessment from the legally operative regulatory decision and from subsequent MAH implementation. A committee recommendation or opinion should not be treated as synonymous with the final binding regulatory decision where a subsequent decision-making step applies.

The practical implementation frameworks described here are governance tools, not universal statutory checklists. Organisational responsibilities and internal quality-system controls may differ between MAHs, provided the applicable regulatory requirements are met.

Regulatory guidance can change. For an active procedure, the current legislation, referral documentation, adopted committee documents, final legally operative decision, current product-information templates and procedure-specific implementation instructions take precedence over this general article.